Washington D.C [USA], Mar. 18: A breakthrough 'gene silencer' drug has the power to 'switch off' heart disease by reducing cholesterol by over 50 percent. The findings come from the largest trial yet to test the safety and effectiveness of this kind of therapy. The technique, known as RNA interference (RNAi) therapy, essentially 'switches off' one of the genes…Read more New ‘gene silencer’ #cholesterol #drug can ‘switch off’ heart #disease

Taro Pharmaceuticals Inc (Canada) has entered into an agreement to acquire all of the issued and outstanding shares of Thallion Pharmaceuticals, a Canadian pharmaceutical corporation, Sun Pharma said in a regulatory filing. Sun Pharmaceuticals Industry today said an indirect arm of its group firm Taro will fully acquire Canada's Thallion Pharmaceuticals for 2.7 million Canadian…Read more #SunPharma indirect arm to acquire #Thallion Pharmaceuticals

India's small and medium-sized generic drugmakers say the threat of tougher rules and higher barriers for outsiders in the U.S. healthcare market will force many to find a niche or focus their expansion efforts on other countries. India supplies nearly a third of medicines sold in the United States, the world's largest healthcare market. Cut-price…Read more Domestic #drugmakers face squeeze in #US healthcare market

Researchers at Cardiff University have devised a new way of creating a drug commonly used as the first line of defence against malaria around the world. Artemisinin is a drug recommended by the World Health Organisation for treatment of all cases of severe malaria and works by attacking all stages of the malaria parasite in…Read more New method for producing leading #antimalarial drug